Kymera Therapeutics (KYMR) Earnings Date, Estimates & Call Transcripts → Biden replacement revealed? (From Paradigm Press) (Ad) Free KYMR Stock Alerts $35.21 -0.50 (-1.40%) (As of 04/24/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 2EstimatedActual EPS (Feb. 22) -$0.25 Beat By $0.19 Consensus EPS (Feb. 22) -$0.44 Read Call TranscriptListen to Call Get Kymera Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for KYMR and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueKYMR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.KYMR Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! Kymera Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244($0.83)($0.57)($0.75)Q2 20244($0.86)($0.41)($0.70)Q3 20244($0.88)($0.73)($0.80)Q4 20244($0.85)($0.17)($0.67)FY 202416($3.42)($1.88)($2.92)KYMR Earnings Date and InformationKymera Therapeutics last released its earnings data on February 22nd, 2024. The reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.19. The firm earned $47.90 million during the quarter, compared to the consensus estimate of $41.94 million. Its quarterly revenue was up 197.5% compared to the same quarter last year. Kymera Therapeutics has generated ($2.52) earnings per share over the last year (($2.52) diluted earnings per share). Earnings for Kymera Therapeutics are expected to decrease in the coming year, from ($3.13) to ($3.42) per share. Kymera Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.Read More Kymera Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/2/2024Estimated)------- 2/22/2024Q4 2023($0.44)($0.25)+$0.19($0.25)$41.94 million$47.90 million 11/2/2023Q3 2023($0.73)($0.90)($0.17)($0.90)$14.53 million$4.73 million8/3/2023Q2 2023($0.70)($0.67)+$0.03($0.67)$13.93 million$16.51 million 5/4/2023Q1 2023($0.69)($0.70)($0.01)($0.70)$14.15 million$9.47 million 2/23/2023Q4 2022($0.57)($0.60)($0.03)($0.60)$20.66 million$16.10 million 11/3/2022Q3 2022($0.70)($0.79)($0.09)($0.79)$16.42 million$9.55 million Get the Latest News and Ratings for KYMR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/9/2022Q2 2022($0.68)($0.78)($0.10)($0.78)$14.97 million$11.51 million 5/3/2022Q1 2022($0.67)($0.71)($0.04)($0.71)$18.66 million$9.62 million 2/24/2022Q4 2021($0.36)($0.66)($0.30)($0.66)$21.31 million$15.30 million 11/10/2021Q3 2021($0.37)($0.56)($0.19)($0.56)$20.18 million$20.34 million8/6/2021Q2 2021($0.25)($0.55)($0.30)($0.55)$18.81 million$18.50 million5/6/2021Q1 2021($0.20)($0.29)($0.09)($0.29)$21.13 million$18.70 million Kymera Therapeutics Earnings - Frequently Asked Questions When is Kymera Therapeutics's earnings date? Kymera Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on KYMR's earnings history. Did Kymera Therapeutics beat their earnings estimates last quarter? In the previous quarter, Kymera Therapeutics (NASDAQ:KYMR) reported ($0.25) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.44) by $0.19. Learn more on analysts' earnings estimate vs. KYMR's actual earnings. How can I listen to Kymera Therapeutics's earnings conference call? The conference call for Kymera Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Kymera Therapeutics's conference call transcript? The conference call transcript for Kymera Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Kymera Therapeutics generate each year? Kymera Therapeutics (NASDAQ:KYMR) has a recorded annual revenue of $78.59 million. How much profit does Kymera Therapeutics generate each year? Kymera Therapeutics (NASDAQ:KYMR) has a recorded net income of -$146.96 million. KYMR has generated -$2.52 earnings per share over the last four quarters. What is Kymera Therapeutics's EPS forecast for next year? Kymera Therapeutics's earnings are expected to decrease from ($3.13) per share to ($3.42) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Beam Therapeutics Earnings Ginkgo Bioworks Earnings Sana Biotechnology Earnings Vericel Earnings Fusion Pharmaceuticals Earnings Recursion Pharmaceuticals Earnings Ambrx Biopharma Earnings Neumora Therapeutics Earnings Denali Therapeutics Earnings Twist Bioscience Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:KYMR) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold GroupWill this $2 AI stock double overnight?Behind the MarketsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
